Last updated: 30 September 2020 at 4:06pm EST

Kevin Ctang Capital Partner... Net Worth




The estimated Net Worth of Kevin Ctang Capital Partner... is at least $17.1 millió dollars as of 28 September 2020. Kevin Partner owns over 110,882 units of Odonate Therapeutics Inc stock worth over $17,067,436 and over the last 6 years Kevin sold ODT stock worth over $0.

Kevin Partner ODT stock SEC Form 4 insiders trading

Kevin has made over 12 trades of the Odonate Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Kevin bought 110,882 units of ODT stock worth $1,455,881 on 28 September 2020.

The largest trade Kevin's ever made was buying 1,052,631 units of Odonate Therapeutics Inc stock on 28 August 2020 worth over $14,999,992. On average, Kevin trades about 208,037 units every 55 days since 2018. As of 28 September 2020 Kevin still owns at least 15,238,782 units of Odonate Therapeutics Inc stock.

You can see the complete history of Kevin Partner stock trades at the bottom of the page.



What's Kevin Partner's mailing address?

Kevin's mailing address filed with the SEC is Executive Dr, San Diego, CA, USA.

Insiders trading at Odonate Therapeutics Inc

Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis és Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.



What does Odonate Therapeutics Inc do?

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.



What does Odonate Therapeutics Inc's logo look like?

Odonate Therapeutics Inc logo

Complete history of Kevin Partner stock trades at Odonate Therapeutics Inc

Dátum
#
Cég
Az érdekelt
Trans.
Tranzakció
Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
28 Sep 2020 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 110,882 $13.13 $1,455,881
28 Sep 2020
15,238,782
28 Aug 2020 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 1,052,631 $14.25 $14,999,992
28 Aug 2020
15,127,900
26 Jun 2019 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 769,231 $26.00 $20,000,006
26 Jun 2019
14,075,269
14 Jun 2019 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 50,000 $26.15 $1,307,500
14 Jun 2019
13,306,038
6 Jun 2019 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 76,308 $27.36 $2,087,787
6 Jun 2019
13,256,038
3 Jun 2019 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 93,692 $24.92 $2,334,805
3 Jun 2019
13,179,730
7 Mar 2019 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 140,000 $18.26 $2,556,400
7 Mar 2019
13,086,038
27 Dec 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 63,700 $13.11 $835,107
27 Dec 2018
12,946,038
20 Dec 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 60,000 $12.60 $756,000
20 Dec 2018
12,882,338
14 Dec 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 40,000 $14.67 $586,800
14 Dec 2018
12,822,338
11 Dec 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 20,000 $15.60 $312,000
11 Dec 2018
12,782,338
6 Dec 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating OfficerChief Financial Officer
Megvenni 20,000 $14.79 $295,800
6 Dec 2018
12,762,338


Odonate Therapeutics Inc executives and stock owners

Odonate Therapeutics Inc executives and other stock owners filed with the SEC include: